Embecta (NASDAQ:EMBC) Issues FY 2026 Earnings Guidance

Embecta (NASDAQ:EMBC) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 2.800-3.00 for the period, compared to the consensus earnings per share estimate of 2.890. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on EMBC. Wall Street Zen raised Embecta from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 27th. BTIG Research reiterated a “buy” rating on shares of Embecta in a report on Tuesday, November 25th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Embecta in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $18.50.

Embecta Stock Down 7.8%

Shares of EMBC traded down $0.88 during midday trading on Thursday, reaching $10.47. 1,649,586 shares of the stock were exchanged, compared to its average volume of 636,609. The company has a market cap of $619.93 million, a price-to-earnings ratio of 6.42 and a beta of 1.11. Embecta has a 12-month low of $9.20 and a 12-month high of $18.12. The firm has a 50 day simple moving average of $11.84 and a 200-day simple moving average of $12.97.

Embecta (NASDAQ:EMBC) last released its quarterly earnings data on Thursday, February 5th. The company reported $0.71 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.04. The firm had revenue of $261.20 million for the quarter, compared to the consensus estimate of $258.07 million. Embecta had a negative return on equity of 24.62% and a net margin of 8.83%.The firm’s revenue was down .3% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.65 earnings per share. Embecta has set its FY 2026 guidance at 2.800-3.00 EPS. Research analysts expect that Embecta will post 2.85 earnings per share for the current fiscal year.

Embecta Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, December 18th. Stockholders of record on Friday, December 5th were issued a dividend of $0.15 per share. The ex-dividend date was Friday, December 5th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 5.7%. Embecta’s dividend payout ratio (DPR) is currently 36.81%.

Hedge Funds Weigh In On Embecta

Institutional investors have recently bought and sold shares of the stock. Larson Financial Group LLC boosted its stake in shares of Embecta by 368.6% during the 3rd quarter. Larson Financial Group LLC now owns 2,001 shares of the company’s stock worth $28,000 after acquiring an additional 1,574 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Embecta by 542.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,371 shares of the company’s stock valued at $71,000 after acquiring an additional 6,224 shares in the last quarter. Wexford Capital LP acquired a new stake in Embecta in the 3rd quarter worth approximately $94,000. Humankind Investments LLC bought a new stake in Embecta during the second quarter worth approximately $111,000. Finally, iSAM Funds UK Ltd acquired a new position in Embecta during the third quarter valued at approximately $115,000. 93.83% of the stock is currently owned by institutional investors.

About Embecta

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.